Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors), Bacterial top IV inhibitors(Bacterial topoisomerase IV inhibitors), GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Otorhinolaryngologic Diseases

Active Indication

Acute otitis mediaOtitis Externa

Inactive Indication

Eye Diseases

Originator Organization

Novartis Pharma AG

Active Organization

Sandoz, Inc.

Inactive Organization

Alcon AG

Drug Highest PhaseApproved

First Approval Date

United States (18 Jul 2003),

Acute otitis mediaOtitis Externa

Regulation-

Structure/Sequence

Molecular FormulaC39H47F2N3O8

InChIKeyNTRHYMXQWWPZDD-WKSAPEMMSA-N

CAS Registry130244-48-3

Clinical Trials associated with Ciprofloxacin/Dexamethasone

NCT00956748

/ WithdrawnPhase 4IIT

N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media

Chronic suppurative otitis media (CSOM) can be particularly difficult to treat as a number of patients do not respond to routine antibiotic or surgical treatments. The current treatment involves administering combination antibiotic anti-inflammatory ear drops such as Ciprodex (ciprofloxacin 0.3% / dexamethasone 0.1%). Although most patients experience a relief of symptoms, a fraction of patients remain refractory to treatment. Recent findings suggest that the addition of N-acetylcysteine (0.5-2%) to Ciprodex is a superior treatment for otitis media with effusion compared to the use of Ciprodex alone.

Start Date29 Nov 2019

Sponsor / Collaborator

St. Paul's Hospital (Grey Nuns) of Saskatoon

NCT02216071

/ CompletedPhase 3

A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa

The purpose of the study is to demonstrate the clinical therapeutic non-inferiority of EXL CDOS to commercially available Ciprofloxacin 0.3% and Dexamethasone 0.1% Sterile Otic Suspension (Ciprodex®, Alcon) in the treatment of acute otitis externa (AOE) when administered twice daily for 7 days.

Start Date20 Jul 2014

Sponsor / Collaborator

Exela Pharma Sciences LLC

NCT01994642

/ TerminatedPhase 3

A Randomized, Double-Blind, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Acute Bacterial Otitis Media in Children With Patent Tympanostomy Tubes

The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis media in children with patent tympanostomy tubes.

Start Date01 Nov 2013

Sponsor / Collaborator

Par Pharmaceutical, Inc.

[+1]

100 Clinical Results associated with Ciprofloxacin/Dexamethasone

100 Translational Medicine associated with Ciprofloxacin/Dexamethasone

100 Patents (Medical) associated with Ciprofloxacin/Dexamethasone

Literatures (Medical) associated with Ciprofloxacin/Dexamethasone

01 Aug 2024·The Laryngoscope

Safety of Nebulized Ciprodex for Postoperative Management of Tracheal Resection

Article

Author: Shuman, Elizabeth A. ; Chwa, Jason S. ; O'Dell, Karla

ObjectiveAnastomotic complications after tracheal resection/cricotracheal resection (TR/CTR), such as granulation tissue formation, can lead to severe morbidity. The off‐label use of nebulized ciprofloxacin‐dexamethasone (Ciprodex) for granulation tissue prophylaxis has anecdotally been used after TR/CTR, especially in pediatric patients. However, its use in the adult population, and its safety and side effect profile post‐TR/CTR has not been reported. This study aims to characterize the incidence of adverse side effects associated with nebulized Ciprodex in post‐TR/CTR patients.MethodsA retrospective review of all patients who underwent TR/CTR from June 2015 to July 2023 was performed. The use of nebulized Ciprodex (1 mL ciprofloxacin‐dexamethasone 0.3%–0.1% otic suspension in 4 mL normal saline) while inpatient was evaluated. Potential side effects were defined as oral thrush, ageusia, arthralgia, and allergic reaction, and were recorded for all patients.ResultsSeventy‐three patients underwent TR/CTR from June 2015 to July 2023. Of these, 53 (72.6%) had documented Ciprodex administration during their postoperative course. One (1.9%) patient reported at least one side effect, including one instance of skin rash (1.9%) and one instance of allergic reaction (1.9%). There were no other side effects attributed to Ciprodex use.ConclusionsThe incidence of side effects related to the use of nebulized Ciprodex is felt to be minimal in post‐TR/CTR. Although Ciprodex may have the potential to treat granulation tissue in the airway, further studies are needed to verify its efficacy and safety.Level of Evidence4 Laryngoscope, 134:3695–3697, 2024

01 Jun 2024·The Laryngoscope

Assessing National Trends and Perceived Safety of Off‐Label Ciprofloxacin‐Dexamethasone Use by Pediatric Otolaryngologists

Article

Author: Rutter, Michael J ; Maurrasse, Sarah E ; Yang, Nan ; Lockwood, Donovan ; Shah, Hemali P ; Rohrbaugh, Tagan ; Shah, Rema

ObjectivesOff‐label use of Ciprodex® (ciprofloxacin‐dexamethasone: CPD), an antibiotic‐steroid combination solution, in the airway has been reported by pediatric otolaryngologists with anecdotal success. We examined national trends regarding off‐label CPD use including prevalence, common indications, prescriber patterns, adverse events, and accessibility.Methods15‐item cross‐sectional survey was distributed to American Society of Pediatric Otolaryngology members from January–April 2022. Univariate analyses were performed to compare responses for users of off‐label CPD versus non‐users. Ease of access was compared across geographies and practice types using multivariate logistic regressions.ResultsOf the 163 complete responses (26.6% response rate), 156 (95.7%) reported using off‐label CPD. Most common indications for off‐label CPD were tracheal granulation (87.8%, n = 137) and choanal atresia (82.1%, n = 128). Ease of access was significantly increased in the Midwest (OR:18.79, 95%CI:3.63–1.24, p = 0.001) and West (OR:29.92, 95%CI:3.55–682.00, p = 0.006). Ease of access was significantly lower at tertiary referral centers (OR:0.11, 95%CI:0.01–0.64, p = 0.041) and private practices (OR:0.04, 95%CI:0.002–0.33, p = 0.009) compared to academic free‐standing children's hospitals. Two‐thirds of respondents reported feeling “Very Comfortable” with the safety profile of off‐label CPD; 99.4% (n = 156) felt that the benefits outweighed the risks of off‐label use. Seven respondents (4.5%) reported adverse events (e.g., local allergic reaction, cushingoid symptoms) from off‐label use.ConclusionsOur findings (26.6% response rate) suggest that off‐label CPD is commonly used by pediatric otolaryngologists, many of whom reported feeling that the benefits of off‐label CPD outweigh the risks. Our results establish a baseline for future efforts to assess the efficacy and safety of off‐label CPD and to improve its accessibility.Level of EvidenceV Laryngoscope, 134:2922–2930, 2024

01 Oct 2023·International Journal of Pediatric Otorhinolaryngology

Otologic safety of intratympanic N-acetylcysteine in an animal model

Article

Author: Salameh, Samer ; Partain, Matthew P ; Daniel, Sam J ; Sayegh, Joseph ; Linn, David T ; Chan, Ching Yee ; Conley, Stephen F ; Wurzba, Sabrina Daniela Silva ; Grenier, Karl

OBJECTIVEN-acetylcysteine (NAC) is an anti-oxidant and mucolytic effective against bacterial biofilms, making it useful in the treatment of chronically discharging ears that are unresponsive to traditional treatment methods. The objective of this study was to evaluate the otologic safety of intratympanic NAC combined with Ciprodex® in an animal model.METHODSBaseline distortion product otoacoustic emissions (DPOAE) and auditory brainstem response (ABR) measurements were performed for both ears on thirteen guinea pigs from the animal care research facilities of the McGill University Health Center. This was followed by intratympanic administration of control solution (Ciprofloxacin 0.3%/Dexamethasone 0.1%) to the left ear and experimental solution (1.25% NAC/Ciprofloxacin 0.3%/Dexamethasone 0.1%) to the right ear. Three additional intratympanic injections were performed over the next fourteen days. DPOAE and ABR measurements were repeated 3-4 weeks after the initial procedure. Outcome measures included differences in DPOAE and ABR thresholds after intervention, clinical evidence of vestibular dysfunction and histological evidence of ototoxicity.RESULTSThere were no significant differences in the ABR thresholds and DPOAE results of the control and experimental ears at baseline and after intervention. There was neither clinical manifestation of vestibular dysfunction nor histological evidence of ototoxicity.CONCLUSIONOur study suggests that intratympanic 1.25% NAC with ciprofloxacin and dexamethasone is safe in guinea pigs and support its potential use in the treatment of chronically discharging ears. Further studies in humans are required to analyze its efficacy relative to conventional treatments.LEVEL OF EVIDENCEAnimal Research.

News (Medical) associated with Ciprofloxacin/Dexamethasone

26 Mar 2024

·www.pharmaceutical-technology.com

Amneal gains FDA greenlight to develop Ciprodex generic for ear infections

Amneal aims to develop an affordable, complex, high-value product for bacterial ear infections. Credits: goodlux/Shutterstock.com. Amneal Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved an abbreviated new drug application (ANDA) for its ciprofloxacin and dexamethasone otic suspension, a generic drug of Novartis ’ Ciprodex (ciprofloxacin/dexamethasone), for the treatment of ear infections. With the FDA approval, the New Jersey-based pharma company will develop an affordable, complex, and high-value product that reflects the “diversification of [the] business” and its evolving portfolio, said Amneal’s generics executive vice-president Andy Boyer in the 25 March press release. An approved ANDA allows a sponsor to manufacture and market a safe and effective generic product at a lower cost than the brand-name product it references. Ciprodex is designed to prevent bacterial DNA replication and the growth of new bacteria via the antibiotic ciprofloxacin. It suppresses inflammation by inhibiting the synthesis of cytokines associated with inflammation. As per its label, the drug is indicated to treat infections caused by susceptible isolates of the designated microorganisms in acute otitis media (AOM) and acute otitis externa (AOE) in patients aged six months and older. Novartis reported a 62% rise in net income in 2023, increasing from $6.04bn to $8.6bn on constant currencies. See Also: J&J’s nipocalimab gains FDA fast track status for FNAIT risk reduction Takeda’s ADZYNMA gains Japanese approval for cTTP treatment Amneal is among several companies marketing generics of Novartis’ combination ear drop medication. India-based Dr Reddy’s launched its Ciprodex generic after receiving FDA approval in August 2020.

Drug ApprovalFast TrackQualified Infectious Disease Product

25 Mar 2024

·www.biospace.com

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

- Product references branded Ciprodex - Represents another complex, high value new product BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension. This product is a combination of ciprofloxacin, a fluoroquinolone antibacterial and dexamethasone, a corticosteroid, and is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa. “This approval represents the addition of another complex, high value medicine,” said Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics. “It reflects the ongoing shift of our leading affordable medicines portfolio towards complex products and the continued successful diversification of our business.” The most common adverse reactions reported with ciprofloxacin and dexamethasone otic suspension were ear pain (2.3%), ear discomfort (3%), and ear pruritus (1.5%). For full prescribing information, see package insert located here. About Amneal Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global pharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 270 pharmaceutical products, primarily within the United States. In its Generics segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit . Cautionary Statement on Forward-Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company. Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the impact of a prolonged business interruption within our supply chain; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties, including recent events affecting the financial services industry; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; the impact of global economic, political or other catastrophic events; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our class A common stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Drug Approval

01 Sep 2021

·www.biospace.com

Dexamethasone Injectables to Remain Top Choice for Addressing Rising Cases of Inflammatory Conditions

COVID-19 Outbreak Fuelled Dexamethasone Demand, Overall Sales to Total US$ 46.9 Bn by 2031 Fact.MR survey on Dexamethasone market offers detailed analysis on the key growth drivers and trends affecting the demand in terms of administration route, application and distribution channel. It also highlights various strategies adopted by key market players to gain a competitive edge in the dexamethasone market. Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest Fact.MR analysis, the global dexamethasone market is set to witness strong growth in the next ten years. Expansion of global antiviral market will have a profound impact on Dexamethasone sales. Fact.MR presents a positive growth outlook for the dexamethasone market with antiviral market set to surpass US$ 46.9 billion by 2031. Robust expansion of the dexamethasone market can be attributed to the increasing prevalence of various diseases such as allergic disorders, skin conditions, cancer, breathing disorders, ulcerative colitis, arthritis and COVID-19. Owing to its anti-inflammatory and immunosuppressant properties, dexamethasone is being increasingly prescribed to treat a wide range of diseases. Sales of dexamethasone skyrocketed during the COVID-19 pandemic as it was found effective in the treatment of some cases of novel coronavirus. Around 2.8 million orders were released in June 2020 after the University of Oxford researchers found dexamethasone effective against symptoms affecting COVID-19 patients. In September 2020, the World Health Organization (WHO) prescribed the use of dexamethasone for the treatment of patients with severe and critical COVID-19. Similarly on August 4, the Food and Drug Administration (FDA) approved an abbreviated new drug application for dexamethasone sodium phosphate injection to treat critically ill COVID-19 patients. Injectable segment dominates the dexamethasone market. They are preferred in hospital emergency wards for treating variety of diseases. Considering this, injectable segment is expected to remain dominant as route of administration through the forecast period. The U.K leads the dexamethasone market with a healthy market share. As per National Health Services (NHS), in June 2020, the U.K government had stockpiled around 200,000 courses of the drug after it showed promising results against COVID-19. “Consistent drug approvals by regulating bodies and increasing manufacturing of will continue to drive the market during the forecast period,” says the Fact.MR analyst. For More Information On How To Improve Your Dexamethasone Market Footprint, Request A Sample Here Key Takeaways from Dexamethasone Market Survey The U.K leads the dexamethasone market as a result of governmental support and increase in manufacturing of generic drug dexamethasone for treating COVID-19. China is expected to offer lucrative growth opportunities for the manufacturers of dexamethasone as majority of raw material comes from the country. With highly developed healthcare sector and presence of leading drug manufacturers, the U.S is set to emerge as a leading market for dexamethasone. The injectable segment leads the dexamethasone market as it is being preferred for its quick action in the treatment of various diseases. Based on application, the COVID-19 segment is anticipated to continue its dominance in the dexamethasone market. Key Drivers Increasing prevalence of various disorders such as chronic obstructive lung diseases and arthritis is driving the dexamethasone market. Advent of COVID-19 pandemic bolstered the sales of dexamethasone products. Involvement of governments to tackle the rising cases of diseases like COVID-19 and cancer is positively impacting the demand for dexamethasone. Expansion of pharmaceutical sector will offer lucrative opportunities to the manufacturers of dexamethasone. Rising awareness regarding the use of dexamethasone also aids in the growth of the market. Key Restraints Development of vaccines will decrease the demand for dexamethasone products. Side effects associated with dexamethasone is restraining the growth of the market. Ask Your Dexamethasone Market Related Questions & Get Customized Reports Competitive Landscape Key companies operating in the dexamethasone market are focusing on developing new products. They have adopted various organic and inorganic strategies such as mergers and acquisitions, advanced product development and collaborations to gain a competitive edge in the market. In August 2020, Dr. Reddy’s Laboratories announced the first-to-market launch of the generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) in the U.S. The Ciprodex is indicated for the treatment of infections caused by the susceptible isolates of the designated microorganism in the specific conditions of Acute Otitis Media (AOM in pediatric and Acute Otitis Externa (AOE) in pediatric, adult and elderly patients. In August 2020, Fera Pharmaceuticals announced the launch of Dexamethasone 4 mg tablets USP in unit dose packaging. In March 2021, the U.S Food and Drug Administration (FDA) approved isatuximab-irfc (sarclisa) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received 1 to 3 lines of therapy. Some of the prominent players operating in the Dexamethasone market profiled by Fact.MR are: Allergan plc Alcon, Pfizer Inc. Morepan laboratories Ltd. Zydus Cadila, Aspen Cadila Pharmaceuticals GLS Pharma Ltd Hikma Pharmaceuticals PLC Merck and Co, Inc. Xspire Pharma, LLC Taro Pharmaceutical Industries Ltd Pragma Pharmaceuticals, LLC Trotwood Pharma Limited Wellona pharma Wokhardt, Sandoz AG. AdvaCare Pharma. More Insights on the Global Dexamethasone Sales Outlook Fact MR provides an unbiased analysis of dexamethasone market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the demand for dexamethasone with a detailed segmentation on the basis of: Route of administration Nasal Ophthalmic Otic Topical Oral Injectable Application Rheumatoid arthritis Psoriasis Eczema Pulmonary diseases COVID-19 Distribution channel Hospital pharmacies Online pharmacies Retail stores Key Questions Covered in the Dexamethasone Sales Outlook Report The report offers insight into dexamethasone demand outlook for 2021-2031 The market study also highlights projected sales growth for dexamethasone market between 2021 and 2031 Dexamethasone market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry Dexamethasone market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others Explore Fact.MR’s Coverage on the Healthcare Domain Rheumatoid Arthritis Stem Cell Therapy Market - Over the forecast period, the global market for rheumatoid arthritis therapeutics is expected to grow moderately. Over the forecast period, the allogeneic mesenchymal stem cell segment is expected to lead the global rheumatoid arthritis stem cell therapy market. As the most accessible channel, hospitals are expected to account for a sizable portion of the global rheumatoid arthritis stem cell therapy market. Medical Ventilators Market - The non-invasive ventilators segment is expected to account for a sizable portion of the medical ventilators market. According to projections, the company will account for more than half of the total medical ventilators market. This is due to its increasing use in homecare and critical care units. The major factor driving intense competition among market players in the global medical ventilators market is the development and launch of technologically advanced innovative products based on patient needs. Medical Oxygen Systems Market - Growing healthcare spending, improved medical facilities, and rapid technological advancements have all contributed to an increase in demand for medical oxygen systems around the world. Because of anatomic changes and muscle loss, the elderly have less pulmonary reserve and cough strength. As a result, they are at a high risk of developing lung disorders and other breathing issues. This has resulted in an increase in demand for medical oxygen systems in recent years. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Source: Fact.MR

Generic DrugCell TherapyVaccineAcquisitionCollaborate

100 Deals associated with Ciprofloxacin/Dexamethasone

External Link

KEGG	Wiki	ATC	Drug Bank
-	Ciprofloxacin/Dexamethasone	S01CA01 S03CA01 S02CA06	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute otitis media	United States	Sandoz, Inc.	18 Jul 2003
Otitis Externa	United States	Sandoz, Inc.	18 Jul 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Otitis Externa	Phase 2	Germany	Alcon AG	-
Otitis Externa	Phase 2	United Kingdom	Alcon AG	-
Otitis Externa	Phase 2	Denmark	Alcon AG	-
Otitis Externa	Phase 2	Spain	Alcon AG	-
Otitis Externa	Phase 2	France	Alcon AG	-
Otitis Externa	Phase 2	Italy	Alcon AG	-
Otitis Media	Phase 2	United Kingdom	Alcon AG	-
Otitis Media	Phase 2	France	Alcon AG	-
Otitis Media	Phase 2	Germany	Alcon AG	-
Otitis Media	Phase 2	Spain	Alcon AG	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02216071 (CTgov)	Phase 3	Acute otitis externa	499	Ciprodex® (Ciprodex®, RLD)	uajectoroj(tlhjavbvrz) = pdqufqrcoc rglefabjkc (zmordqnenu, ijanjydwyd - bsirblfwwk) View more	-	28 May 2021
				Dexamethasone 0.1%) Sterile Otic Suspension (EXL CDOS)	uajectoroj(tlhjavbvrz) = dpyhcdjjay rglefabjkc (zmordqnenu, itbaknzkgl - gitkqxedrn) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis